BioMarin Pharmaceutical Inc.
BMRN
Price:
$84.08
Market Cap:
$16.01B
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcu...[Read more]
Industry
Biotechnology
IPO Date
1999-07-26
Stock Exchange
NASDAQ
Ticker
BMRN
The ROE as of September 2024 (TTM) for BioMarin Pharmaceutical Inc. (BMRN) is 5.08%
According to BioMarin Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current ROE is 5.08%. This represents a change of 305.42% compared to the average of 1.25% of the last 4 quarters.
BioMarin Pharmaceutical Inc. (BMRN) Historical ROE (quarterly & annually)
How has BMRN ROE performed in the past?
The mean historical ROE of BioMarin Pharmaceutical Inc. over the last ten years is -2.05%. The current 5.08% ROE has changed -348.01% with respect to the historical average. Over the past ten years (40 quarters), BMRN's ROE was at its highest in in the September 2020 quarter at 19.36%. The ROE was at its lowest in in the June 2016 quarter at -22.09%.
Average
-2.05%
Median
-2.05%
Minimum
-22.78%
Maximum
20.80%
BioMarin Pharmaceutical Inc. (BMRN) ROE by Quarter and Year
Discovering the peaks and valleys of BioMarin Pharmaceutical Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 218.37%
Maximum Annual ROE = 20.80%
Minimum Annual Increase = -2823.25%
Minimum Annual ROE = -22.78%
| Year | ROE | Change |
|---|---|---|
| 2023 | 3.39% | 10.09% |
| 2022 | 3.08% | -304.96% |
| 2021 | -1.50% | -107.21% |
| 2020 | 20.80% | -2823.25% |
| 2019 | -0.76% | -70.64% |
| 2018 | -2.60% | -37.57% |
| 2017 | -4.17% | -81.71% |
| 2016 | -22.78% | 218.37% |
| 2015 | -7.16% | -18.39% |
| 2014 | -8.77% | -33.32% |
BioMarin Pharmaceutical Inc. (BMRN) Average ROE
How has BMRN ROE performed in the past?
The current ROE of BioMarin Pharmaceutical Inc. (BMRN) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
1.65%
5-year avg
5.00%
10-year avg
-2.05%
BioMarin Pharmaceutical Inc. (BMRN) ROE vs. Peers
How is BMRN’s ROE compared to its peers?
BioMarin Pharmaceutical Inc.’s ROE is greater than Seagen Inc. (-28.06%), less than Alnylam Pharmaceuticals, Inc. (47.92%), less than Exelixis, Inc. (15.80%), less than Halozyme Therapeutics, Inc. (168.60%), greater than Arrowhead Pharmaceuticals, Inc. (-172.90%), less than Incyte Corporation (2.10%), greater than Ionis Pharmaceuticals, Inc. (-115.80%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Vaxcyte, Inc. (-30.07%), greater than Liquidia Corporation (-183.58%), greater than Legend Biotech Corporation (-23.20%), less than Bio-Techne Corporation (8.36%), greater than Mereo BioPharma Group plc (-63.39%), greater than Blueprint Medicines Corporation (-85.25%), greater than Agios Pharmaceuticals, Inc. (-47.05%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than IVERIC bio, Inc. (-38.66%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Karuna Therapeutics, Inc. (-30.79%),
| Company | ROE | Market cap |
|---|---|---|
| -28.06% | $43.15B | |
| 47.92% | $31.68B | |
| 15.80% | $7.17B | |
| 168.60% | $7.50B | |
| -172.90% | $2.76B | |
| 2.10% | $11.80B | |
| -115.80% | $6.86B | |
| -139.02% | $5.00B | |
| -30.07% | $12.45B | |
| -183.58% | $698.44M | |
| -23.20% | $9.90B | |
| 8.36% | $11.34B | |
| -63.39% | $664.26M | |
| -85.25% | $5.47B | |
| -47.05% | $2.46B | |
| -122.70% | $1.25B | |
| -38.66% | $5.51B | |
| -46.15% | $161.36M | |
| -30.79% | $12.60B |
Build a custom stock screener for BioMarin Pharmaceutical Inc. (BMRN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioMarin Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
BioMarin Pharmaceutical Inc. (BMRN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like BioMarin Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is BioMarin Pharmaceutical Inc.'s ROE?
How is the ROE calculated for BioMarin Pharmaceutical Inc. (BMRN)?
What is the highest ROE for BioMarin Pharmaceutical Inc. (BMRN)?
What is the 3-year average ROE for BioMarin Pharmaceutical Inc. (BMRN)?
What is the 5-year average ROE for BioMarin Pharmaceutical Inc. (BMRN)?
How does the current ROE for BioMarin Pharmaceutical Inc. (BMRN) compare to its historical average?